SIGLEC1 and viral load: Since the onset of SARS-CoV-2 pandemic in 2019, a series of both retrospective and prospective clinical studies, investigating the diagnostic performance and discriminative ability of (monocytic) CD169 as a host-based biomarker of acute viral disease have been performed.